{
  "id": 17680266,
  "title": "1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November",
  "url": "https://urgent.news/2026/11/01/1-dividend-paying-biotech-stock-to-buy-hand-over-fist-in-november",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-01T20:42:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/01/1-dividend-paying-biotech-stock-to-buy-hand-over-f/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "In November, investors may want to consider purchasing Gilead Sciences (GILD) amid ongoing enthusiasm for AI stocks. While Gilead Sciences' shares have surged 39% this year, outpacing the S&P 500's 11% growth, the biotech company is also attracting attention from income-focused investors. Gilead Sciences' strong performance in 2026 can be attributed to excellent financial results, with revenue growing 7% year over year to $8.3 billion. Despite a decline in coronavirus drug sales, the company's core therapeutic areas, HIV and liver disease, have shown growth. HIV product sales increased 18% year over year to $6.2 billion, with Biktarvy and Descovy driving the growth. The liver disease segment saw revenue rise 13% year over year to $927 million, benefiting from Biktarvy and Descovy for PrEP, as well as Gilead Sciences' expanding HIV and liver disease portfolios. The approval of Bixlenvo, a convenient HIV regimen, and Hepcludex for chronic hepatitis delta virus infection, has further bolstered Gilead Sciences' prospects. Additionally, the label expansion of Trodelvy for metastatic triple-negative breast cancer has expanded its addressable market. These regulatory milestones are expected to generate substantial revenue for the company. Gilead Sciences has been expanding its approved portfolio, and its HIV business shows promise with the long-term dominance of Biktarvy, which won't face generics in the U.S. until 2036. The stock is reasonably valued, trading at 16.8x forward earnings, compared to the healthcare sector's average of 19.3x. Additionally, Gilead Sciences offers a dividend yield of 2%, above the S&P 500's average of 1.1%, and has increased payouts by 74.5% over the past decade, making it an attractive income stock for long-term investors.",
  "summary": "The company is having a great year.",
  "key_points": [
    "Gilead Sciences shares surged 39% in 2024, outpacing S&P 500's 11% growth",
    "Biotech company's HIV and liver disease segments grew 18% and 13% respectively in 2024",
    "Gilead Sciences offers 2% dividend yield, up 74.5% over the past decade"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November",
        "url": "https://urgent.news/2026/11/01/1-dividend-paying-biotech-stock-to-buy-hand-over-fist-in-november-17695221",
        "published": "2026-11-01T21:02:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}